Showing results (7641-7650 of 10,083) with videos related to
Sort By:
Pageof 1,009
Current Pharmaceutical Design|January 14, 2012
Abnormal bodily experiences may be a marker of early schizophrenia?Giovanni Stanghellini, Massimo Ballerini, Paolo Fusar Poli, et al.Current Pharmaceutical Design|January 14, 2012
Neurocognition in the psychosis risk syndrome: a quantitative and qualitative reviewAnthony J Giuliano, Huijun Li, Raquelle I Mesholam-Gately, et al.Current Pharmaceutical Design|January 14, 2012
Glutamate and psychosis riskAlice Egerton, Paolo Fusar-Poli, James M StoneCurrent Pharmaceutical Design|January 14, 2012
Neurophysiological alterations in the prepsychotic phasesNicolas A Crossley, Miguel Constante, Paolo Fusar-Poli, et al.Current Pharmaceutical Design|January 14, 2012
Brain structural abnormalities at the onset of schizophrenia and bipolar disorder: a meta-analysis of controlled magnetic resonance imaging studiesLuca De Peri, Alessandra Crescini, Giacomo Deste, et al.Current Pharmaceutical Design|January 14, 2012
Pharmacological prevention and treatment in clinical at-risk states for psychosisStephan Ruhrmann, Joachim Klosterkötter, Mitja Bodatsch, et al.Current Pharmaceutical Design|January 14, 2012
Ethical implications for clinical practice and future research in "at risk" individualsFiza Singh, Heline Mirzakhanian, Paolo Fusar-Poli, et al.Current Pharmaceutical Design|January 11, 2012
Beta-arrestin biased agonism/antagonism at cardiovascular seven transmembrane-spanning receptorsAnastasios LymperopoulosCurrent Pharmaceutical Design|January 11, 2012
Probing heterotrimeric G protein activation: applications to biased ligandsColette Denis, Aude Saulière, Segolene Galandrin, et al.Current Pharmaceutical Design|January 11, 2012
Phenotypes and enviromental factors: their influence in PCOSEvanthia Diamanti-Kandarakis, Charikleia Christakou, Evangelos MarinakisPageof 1,009